Skip to content

Author

Benjamin J. Solomon

We have 2 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Complement-driven NETosis mediates immunotherapy resistance in STK11-mutant lung adenocarcinoma.

PURPOSE Lung adenocarcinomas (LUADs) harboring concurrent mutations in KRAS and STK11 define a clinically aggressive subgroup characterized by primary resistance to immune checkpoint inhibitors (ICIs). In contrast, KRAS/TP53 co-mutant tumors typically exhibit an inflamed tumor microenvironment (TME) and improved respon...

Carlos E. de Andrea, D. Ajona, C. Sainz et al. · 0 citations
Open access Aug 2026

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.

K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.